EU gives positive opinion on EpiCepts Ceplene in AML

Posted on July 25, 2008 by crimsoncanary

EpiCept have received a positive opinion from the CHMP for Ceplene (histamine dihydrochloride), for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission.

Filed under: gpcr | Tagged: , , , , , , | Leave a comment »

EpiCepts Ceplene improves Leukemia Free Survival in Acute Myeloid Leukemi

Posted on June 12, 2008 by crimsoncanary

Data presented at the European Hematology Association Congress show EpiCept’s Histamine H2 agonist Ceplene to improve leukemia free survival (LFS) in acute myeloid leukemia (AML) patients.

Filed under: gpcr | Tagged: , , , , , , | Leave a comment »

EpiCept re-file Ceplene in Europe

Posted on May 27, 2008 by crimsoncanary

EpiCept have filed re-examination MAA documents in Europe for Ceplene, its histamine dihydrochloride compound that is intended for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML). The EU CHMP previously issued a negative opinion, requiring further mechanistic data

Filed under: gpcr | Tagged: , , , , , | Leave a comment »